Synairgen (SNG) Earns Corporate Rating from FinnCap

Synairgen (LON:SNG)‘s stock had its “corporate” rating reiterated by FinnCap in a research note issued to investors on Tuesday, November 21st.

Separately, N+1 Singer reissued an “under review” rating on shares of Synairgen in a research report on Wednesday, September 6th.

Synairgen (LON:SNG) remained flat at $GBX 10.75 ($0.14) during midday trading on Tuesday. 22,000 shares of the company traded hands, compared to its average volume of 64,351. Synairgen has a fifty-two week low of GBX 6.88 ($0.09) and a fifty-two week high of GBX 32 ($0.43).

TRADEMARK VIOLATION NOTICE: “Synairgen (SNG) Earns Corporate Rating from FinnCap” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://ledgergazette.com/2017/12/06/finncap-reaffirms-corporate-rating-for-synairgen-plc-sng.html.

About Synairgen

Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment or prevention of asthma exacerbations caused by the common cold; IFN-ß that is in Phase-I clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold; and LOXL2 inhibitor, which is in preclinical development for the treatment of idiopathic pulmonary fibrosis (IPF).

Receive News & Ratings for Synairgen plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply